CLOVClover Health Investments, Corp.
Price
+58%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality strong, hard red flags, demanding price, growing in the filings, the market undecided.
(1)Represents full year 2025 Benefits expense ratio (“BER”) for Clover Health, as well as most recent results of other public companies with “Traditional MA Plan” approaches that have reported results as of the time of this publication. BER is a non-GAAP financial measure. We calculate our BER by taking the total of Insurance net medical expenses incurred and quality improvements, and dividing that total by premiums earned on a net basis, in a given period.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Clover Health Investments, Corp. (CLOV) reported revenue of $743M in Q2 2026 (quarter ended Jun 30, 2026), up 56% from the same quarter a year earlier. That came with net income of $28M (3.8% of revenue). For the full year FY2025, revenue was $1.92B (+40% year on year) and net income −$86M. Its largest segment in Q2 2025 (quarter ended Jun 30, 2025) was Insurance at $16M, 50.0% of the disclosed total, just ahead of Insurance at 50.0%. The next results filing is expected around Nov 4, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 9, 2026Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027.Regulation FD disclosure · press release
- Sep 25, 2026On September 22, 2026, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board.Director or officer change · Form 8-K/A
- Sep 24, 2026On September 22, 2026, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2025 · $32.4MThe company’s own SEC segment disclosure.
- Insurance$16.2M50%
- Insurance$16.2M50%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.